The role of ibrutinib in Waldenström macroglobulinemia

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: IARC. 4th ed. Vol. 2, 2017.
   Google Scholar
• Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenstrom macroglobulinemia: an analysis of the surveillance, epidemiology and end results database. Blood. 2014;123:3999–4000.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Br J Haematol. 2015;169:81–89.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–833.
   PubMed Web of Science ®Google Scholar
• Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia. 2013;27:1722–1728.
   PubMed Web of Science ®Google Scholar
• Mori N, Ohwashi M, Yoshinaga K, et al. L265P mutation of the MYD88 gene is frequent in Waldenstrom’s macroglobulinemia and its absence in myeloma. Plos One. 2013;8:e80088.
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121:4504–4511.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522–2528.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373:584–586.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122:1222–1232.
   PubMed Web of Science ®Google Scholar
• Honigberg L, Smith A, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Hutchinson C, Dyer M. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2014;166:12–22.
   PubMed Web of Science ®Google Scholar
• Yang G, Buhrlage S, Tan L,Z, et al. Hck is a highly relevant target of ibrutinib in MYD88 mutated Waldenstrom’s macroglobulinemia and diffuse large B-cell lymphoma. In: 57th Annual Meeting and Exposition. Orlando, FL, USA; 2015 Dec 5–8.
   Google Scholar
• Advani R, Buggy J, Sharman J, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Furman R, Bilotti E, Graef T. Single agent ibrutinib demonstrates long-term activity and safety in patients with relapsed/refractory Leuk Lymphoma. 2017;58:1502–1505.
   Google Scholar
• Treon S, Tripsas C, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib monotherapy for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2016;18:241–250, 2017.
   PubMedGoogle Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom’s macroglobulinemia. ASH 2017 poster abstract no 2767; 2017 Dec 10; Atlanta, Georgia
   Google Scholar
• Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Byrd J, O’Brien S, James D. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1278–1279.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 369:507–516.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor dependent platelet functions. Blood. 2014;124:3991–3995.
   PubMed Web of Science ®Google Scholar
• Rigg R, Aslan J, Healy L, et al. Oral administration of Bruton’s tyrosine kinase (BTK) inhibitors impairs GPVI-mediated platelet function. Am J Physiol Cell Physiol. 2015;310:C373–C380.
   PubMed Web of Science ®Google Scholar
• McMullen J, Boey E, Ooi J, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–3830.
   PubMed Web of Science ®Google Scholar
• Pretorius L, Du X, Woodcock E, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175:998–1009.
   PubMed Web of Science ®Google Scholar
• Gustine J, Meid K, Toni Dubeau, NP, et al. Ibrutinib discontinuation in Waldenström macroglobulinemia: etiologies, outcomes, and IgM. In: ASH 2017 oral abstract no 802; Atlanta, Georgia; 2017 Dec 11.
   Google Scholar
• Gustine J, Meid K, Toni Dubeau, NP et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. ASH 2017 poster abstract no 4051; 2017 Dec 11; Atlanta, Georgia
   Google Scholar
• Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol. 2014;161:43–56.
   Web of Science ®Google Scholar
• Eda H, Santo L, Cirstea D, et al. A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia. 2014;28:1892–1901.
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Gopal A, Kahl B, de Vos S, et al. Pi3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Kashyap MK, Kumar D, Jones H, et al. Ulocuplumab (BMS-936564/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016;7:2809–2822.
   PubMed Web of Science ®Google Scholar